{"id":692763,"date":"2022-10-06T07:22:20","date_gmt":"2022-10-06T11:22:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/"},"modified":"2022-10-06T07:22:20","modified_gmt":"2022-10-06T11:22:20","slug":"taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/","title":{"rendered":"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DALLAS, Oct.  06, 2022  (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced\u00a0two poster\u00a0presentations\u00a0at the\u00a0upcoming\u00a029<sup>th<\/sup>\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0in cooperation with the British Society of Gene &amp; Cell Therapy (BSGCT)\u00a0taking place in\u00a0Edinburgh,\u00a0Scotland\u00a0from\u00a0October 11-14, 2022.\u00a0\u00a0<br \/>\u00a0\u00a0<br \/><strong>Poster\u00a0Presentation Details<\/strong><\/p>\n<ul type=\"disc\">\n<li>P238:<strong>\u00a0<\/strong><em>Assessment of Safety and Biodistribution of a miniMECP2 AAV9 Vector for Gene-replacement Therapy of Rett Syndrome in Non-human Primates (NHPs)\n<p><\/em>Presenter \u2013 Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene Therapies<br \/>Date and Time \u2013 Thursday, October 13<sup>th<\/sup>\u00a0at 17:30 GMT + 1\/12:30 PM Eastern Time<br \/>Location \u2013\u00a0Cromdale Hall<strong>\u00a0<\/strong>\u00a0<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>P206<strong>:\u00a0<\/strong><em>Assessment of Safety of miniMECP2 AAV9 vector (TSHA-102) for Gene-replacement Therapy of Rett Syndrome in Rats\n<p><\/em>Presenter \u2013 Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene Therapies<br \/>Date and Time \u2013 Thursday, October 13<sup>th<\/sup>\u00a0at 17:30 GMT + 1\/12:30 PM Eastern Time<br \/>Location \u2013\u00a0Cromdale Hall\u00a0\u00a0<\/li>\n<\/ul>\n<p align=\"left\">Additional details can be found at\u00a0the\u00a0ESGCT 29<sup>th<\/sup>\u00a0Annual Meeting\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xThQ0mOrZrgE_LF7pBdJ31vA4c2gmSmaxz3sKLzV-G2DzgeUR28hGYPfshDaJLRLq1frdbERQK47ttobIMB1xg==\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a>.<br \/>\u00a0\u00a0<br \/><strong>About Taysha Gene Therapies\u00a0<\/strong>\u00a0<br \/>\u00a0\u00a0<br \/>Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team\u2019s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform\u2014an engine for potential new cures\u2014with a goal of dramatically improving patients\u2019 lives. More information is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0b4N9n84fDdtPMywBQ8DU5ABXWNwiZSWq7zH7pyNGpTrkSpEGePXETPeGT1HdmCzX8Ji7OGUeS6kBU7kNcQOdw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.tayshagtx.com<\/u><\/a>.\u00a0<br \/>\u00a0\u00a0<br \/><strong>Company Contact:<\/strong><br \/>Kimberly Lee, D.O.\u00a0<br \/>Chief Corporate Affairs Officer\u00a0<br \/>Taysha Gene\u00a0Therapies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QSKiDS6Nikv1EHV_PSA1Ed9D-53II_5SZygi2NlCNLSVOFvP7tx9pBr_VoYMBvwr7m9wdoXctD2tjHpU0aVM_UY4hJwX2PwdrfhK1_-AWkg=\" rel=\"nofollow noopener\" target=\"_blank\">klee@tayshagtx.com<\/a>\u00a0<br \/>\u00a0\u00a0<br \/><strong>Media Contact:<\/strong><strong>\u00a0<\/strong><br \/>Carolyn Hawley\u00a0<br \/>Evoke Canale<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5fOL1lGLH5-6xawDePPPaasmvieBtTTC5PYmDq4QiomM_blUNvbpxp__QnoWUhm1DbahHqmIg8VrrWRc0DKx_XUVLhzzvhVH4J-oCnXVMF3kC6NgbnMFwPdByU8IQHKr\" rel=\"nofollow noopener\" target=\"_blank\">carolyn.hawley@evokegroup.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmQzZjc3MDMtZGEyNi00NDc0LTgyNmYtODVjNmYyY2Y5OTRkLTUwMDEwMzIzNw==\/tiny\/Taysha-Gene-Therapies-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced\u00a0two poster\u00a0presentations\u00a0at the\u00a0upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0in cooperation with the British Society of Gene &amp; Cell Therapy (BSGCT)\u00a0taking place in\u00a0Edinburgh,\u00a0Scotland\u00a0from\u00a0October 11-14, 2022.\u00a0\u00a0\u00a0\u00a0Poster\u00a0Presentation Details P238:\u00a0Assessment of Safety and Biodistribution of a miniMECP2 AAV9 Vector for Gene-replacement Therapy of Rett Syndrome in Non-human Primates (NHPs) Presenter \u2013 Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene TherapiesDate and Time \u2013 Thursday, October 13th\u00a0at 17:30 GMT + 1\/12:30 PM Eastern TimeLocation \u2013\u00a0Cromdale &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692763","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced\u00a0two poster\u00a0presentations\u00a0at the\u00a0upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0in cooperation with the British Society of Gene &amp; Cell Therapy (BSGCT)\u00a0taking place in\u00a0Edinburgh,\u00a0Scotland\u00a0from\u00a0October 11-14, 2022.\u00a0\u00a0\u00a0\u00a0Poster\u00a0Presentation Details P238:\u00a0Assessment of Safety and Biodistribution of a miniMECP2 AAV9 Vector for Gene-replacement Therapy of Rett Syndrome in Non-human Primates (NHPs) Presenter \u2013 Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene TherapiesDate and Time \u2013 Thursday, October 13th\u00a0at 17:30 GMT + 1\/12:30 PM Eastern TimeLocation \u2013\u00a0Cromdale &hellip; Continue reading &quot;Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T11:22:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0\",\"datePublished\":\"2022-10-06T11:22:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/\"},\"wordCount\":335,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/\",\"name\":\"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==\",\"datePublished\":\"2022-10-06T11:22:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/","og_locale":"en_US","og_type":"article","og_title":"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0 - Market Newsdesk","og_description":"DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced\u00a0two poster\u00a0presentations\u00a0at the\u00a0upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0in cooperation with the British Society of Gene &amp; Cell Therapy (BSGCT)\u00a0taking place in\u00a0Edinburgh,\u00a0Scotland\u00a0from\u00a0October 11-14, 2022.\u00a0\u00a0\u00a0\u00a0Poster\u00a0Presentation Details P238:\u00a0Assessment of Safety and Biodistribution of a miniMECP2 AAV9 Vector for Gene-replacement Therapy of Rett Syndrome in Non-human Primates (NHPs) Presenter \u2013 Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene TherapiesDate and Time \u2013 Thursday, October 13th\u00a0at 17:30 GMT + 1\/12:30 PM Eastern TimeLocation \u2013\u00a0Cromdale &hellip; Continue reading \"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T11:22:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0","datePublished":"2022-10-06T11:22:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/"},"wordCount":335,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/","name":"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==","datePublished":"2022-10-06T11:22:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTUwMiM1MTg4OTI5IzUwMDEwMzIzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-announces-presentations-at-the-upcoming-29th-annual-meeting-of-the-european-society-of-gene-cell-therapy-esgct\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Taysha Gene Therapies\u00a0Announces Presentations at\u00a0the\u00a0Upcoming\u00a029th\u00a0Annual Meeting of the\u00a0European\u00a0Society of Gene &amp; Cell Therapy\u00a0(ESGCT)\u00a0\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692763"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692763\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}